 I-Mab NASDAQ: IMAB has announced topline results from its Phase 2 study evaluating olamkicept also known as TJ301 in patients with active ulcerative colitis UC. The study met its primary endpoint and provided early evidence that I-Mabs IL-6 inhibitor improves outcomes, including rectal bleeding. 